MGO One Seven LLC Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• MGO One Seven LLC acquired a new stake in Teva Pharmaceutical Industries Ltd., purchasing 14,059 shares valued at approximately $236,000 in the 2nd quarter.
• Institutional investors have significantly increased their holdings in Teva, with Bourgeon Capital Management growing its stake by over 100% and Jump Financial LLC's stake increasing by 172.1%.
• Teva reported a Q2 EPS of $0.66, beating estimates, while setting a FY 2025 guidance of 2.500-2.600 EPS, despite a slight revenue decline for the quarter.

MGO One Seven LLC acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 14,059 shares of the company's stock, valued at approximately $236,000.

Other institutional investors also recently made changes to their positions in the company. Bourgeon Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock valued at $12,134,000 after buying an additional 363,252 shares during the period. Amundi grew its stake in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company's stock valued at $10,080,000 after buying an additional 105,846 shares during the period. IFM Investors Pty Ltd increased its position in shares of Teva Pharmaceutical Industries by 9.4% in the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock worth $3,797,000 after acquiring an additional 19,447 shares in the last quarter. Jump Financial LLC increased its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock worth $20,373,000 after acquiring an additional 838,423 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock worth $38,487,000 after acquiring an additional 134,705 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $19.43 on Tuesday. The company has a fifty day simple moving average of $18.95 and a 200 day simple moving average of $17.17. The firm has a market cap of $22.28 billion, a price-to-earnings ratio of -121.41, a PEG ratio of 1.06 and a beta of 0.71. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the prior year, the firm posted $0.61 EPS. The firm's revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 11th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $25.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.